Philip Morris International Inc. (NYSE:PM) Q3 2023 Earnings Call Transcript

Andrei Condrea: Hi. Good morning, Emmanuel. Just one from me, please. And I know it’s a bit of a topic to [Joe] (ph), but the GLP-1 drug, obviously, there’s been talk about it having anti-addictive properties. Do you think this could be an issue for PMI in the long term, rather? Thank you.

Emmanuel Babeau: Frankly, I mean, I’ve been hearing things about that. I mean I know what the assumption is everybody going to be under GLP-1, and therefore, they’re going to drive massive change in consumer behavior. And I’m not even able to tell you what would be the impact for somebody who is a nicotine user and is going to take GLP-1. I’m not sure we have any serious study on human behavior on that that is going to say that. So first of all, I don’t know how broad the usage of this medicine as drug is going to be. Second, I don’t know what’s going to be the potential impact. So I’m not sure that today we can say anything relevant and that makes sense on that topic.

Andrei Condrea: No. That makes sense. Thank you very much.

Emmanuel Babeau: Thank you.

Operator: Thank you. And there are no further questions at this time. I’ll turn the call back to Emmanuel for closing remarks.

James Bushnell: Hi. This is James Bushnell, Vice President of Investor Relations. That concludes our call today. Thank you again for joining us. If you have any follow-up questions, please contact the Investor Relations team. Thank you again, and have a great day.

Emmanuel Babeau: Thank you, talk to you soon. Bye-bye.

Operator: This does conclude today’s call. We thank you for your participation. You may disconnect at any time.